Novartis | NOVN - Interest Expense On Debt

Stock Price
116.68
Daily Change
-0.12 -0.10%
Monthly
-0.63%
Yearly
27.56%
Q2 Forecast
114.36

Novartis reported $343M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alcon AG USD 52M 2M Mar/2026
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Autolus Therapeutics Ltd USD 22.84M 12.32M Dec/2025
Bayer EUR 675M 87M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Fresenius EUR 81M 5M Sep/2025
Fresenius Medical Care EUR 79M 6M Mar/2026
Genmab DKK 10M 27M Dec/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
GRIFOLS EUR 141.43M 61.28M Jun/2025
Hikma Pharmaceutical USD 67M 47M Dec/2025
J&J USD 43M 25M Mar/2026
Lakefront Biotherapeutics EUR 1.72M 940K Sep/2025
Lonza CHF 84M 14M Jun/2025
Merck EUR 121M 5M Dec/2025
Merck USD 479M 67M Mar/2026
Novartis USD 343M 39M Mar/2026
Novartis USD 281M 8M Sep/2025
Novo Nordisk DKK 1.53B 3.43B Sep/2025
Orion EUR 1.4M 800K Mar/2026
Pfizer USD 671M 40M Mar/2026
Philips EUR 83M 26M Mar/2026
Recordati EUR 22.13M 1.43M Dec/2025
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 178M 203M Mar/2026
UCB EUR 49M 29M Dec/2025